List view / Grid view
The new $6.5 billion Houston site will manufacture active pharmaceutical…
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
The new $5 billion manufacturing site is set to become…
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
The expansion is planned to support production of Eli Lilly…
The expansion is planned to support production of Eli Lilly and Company’s medicines for diabetes, obesity and Alzheimer's and both sites will harness advanced technology and sustainability capabilities.
Once operational in 2027, Eli Lilly’s new $2.5 billion German…
Once operational in 2027, Eli Lilly’s new $2.5 billion German manufacturing site will play a vital role in supporting the company’s incretin supply.
A total $3.7 billion investment at LEAP Innovation Park in…
A total $3.7 billion investment at LEAP Innovation Park in the US is Eli Lilly and Company’s largest manufacturing investment at a single location in its history.
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-300x278.jpg)
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-e1629971959212.jpg)
The new North Carolinian site will increase parenteral and device…
The new North Carolinian site will increase parenteral and device manufacturing capacity and create 600 new jobs.
